{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:37:49Z","timestamp":1791092269533,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.ejca.2010.08.001","type":"journal-article","created":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T08:31:42Z","timestamp":1283848302000},"page":"3243-3250","source":"Crossref","is-referenced-by-count":152,"title":["Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies"],"prefix":"10.1016","volume":"46","author":[{"given":"Christophe","family":"Le Tourneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Delbaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Girre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Chiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Armour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheelagh","family":"Frame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athos","family":"Gianella-Borradori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.08.001_b0005","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/ar0201198","article-title":"Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials","volume":"36","author":"Meijer","year":"2003","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.ejca.2010.08.001_b0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0092-8674(00)81079-X","article-title":"Role of the INK4a locus in tumor suppression and cell mortality","volume":"85","author":"Serrano","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2010.08.001_b0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev.med.50.1.401","article-title":"The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer","volume":"50","author":"Tsihlias","year":"1999","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ejca.2010.08.001_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/excr.1997.3776","article-title":"The retinoblastoma protein pathway in cell cycle control and cancer","volume":"237","author":"Bartek","year":"1997","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ejca.2010.08.001_b0025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.10738","article-title":"In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)","volume":"102","author":"McClue","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.08.001_b0030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0026-895X(24)12306-1","article-title":"The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382","volume":"60","author":"Ljungman","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ejca.2010.08.001_b0035","first-page":"95","article-title":"Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells","volume":"21","author":"Mihara","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2010.08.001_b0040","first-page":"3119","article-title":"Antitumor activity of CYC202, a cyclin-dependent kinase inhibitor, in human tumor xenografts in vitro","volume":"44","author":"Maier","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2010.08.001_b0045","first-page":"16","article-title":"Schedule dependency of combining CYC202 (R-roscovitine), a cyclin-dependent kinase inhibitor, with docetaxel in human tumor xenografts in vivo","volume":"9","author":"Fiebig","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2010.08.001_b0050","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/1078-0432.CCR-04-2264","article-title":"In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202","volume":"11","author":"Raynaud","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.08.001_b0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.08.001_b0060","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/0008-5472.CAN-03-2455","article-title":"Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18","volume":"64","author":"Kramer","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.08.001_b0065","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jcb.10173","article-title":"Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis","volume":"85","author":"Sheard","year":"2002","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ejca.2010.08.001_b0070","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/JCO.2002.09.030","article-title":"Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer","volume":"20","author":"Raymond","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.08.001_b0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10637-005-6730-3","article-title":"Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam","volume":"23","author":"van Kesteren","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2010.08.001_b0080","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2002.01.043","article-title":"Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms","volume":"20","author":"Tan","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.08.001_b0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.08.001_b0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10637-007-9090-3","article-title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","volume":"26","author":"Heath","year":"2008","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2010.08.001_b0095","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/annonc\/mdp377","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours","volume":"21","author":"Boss","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.08.001_b0100","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1158\/0008-5472.CAN-03-0110","article-title":"The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway","volume":"64","author":"Whittaker","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.08.001_b0105","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-04-0229","volume":"10","author":"Haddad","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.08.001_b0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2893.2005.00594.x","article-title":"Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C","volume":"12","author":"Kronenberger","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ejca.2010.08.001_b0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1309\/UK621LFJ4FX07KDE","article-title":"Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections","volume":"121","author":"Grassi","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2010.08.001_b0120","first-page":"86","article-title":"Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia","volume":"24","author":"Tramonti","year":"2000","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.ejca.2010.08.001_b0125","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-08-1748","article-title":"Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer","volume":"15","author":"Hsieh","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910007823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910007823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:20:02Z","timestamp":1740500402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910007823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":25,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0959804910007823"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.08.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}